Distinguishing Clonal Hematopoiesis from Tumor HRR Alterations in Liquid Biopsy: Implications for PARP Inhibitor Use in #mCRPC. Presented by @EAntonarakis @UMNCancer, #ESMO26 writt

UroToday.com· @urotoday · X·2026-10-24 04:00· 2 days agoScore45

Body · original

Distinguishing Clonal Hematopoiesis from Tumor HRR Alterations in Liquid Biopsy: Implications for PARP Inhibitor Use in #mCRPC. Presented by @EAntonarakis @UMNCancer, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4soadIo #ProstateCancer #PrecisionOncology @myESMO

285 views · 3 likes · 3 reposts · 0 replies

Conference abstracts

2218RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)

https://esmocongress.esmo.org

2220RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)

https://esmocongress.esmo.org

Source: UroToday.com · x.com